Feb 15, 2022, 2:55 PM
(from EdWeek) The U.S. Food and Drug Administration has canceled a meeting of its vaccine advisory committee, which was scheduled for this week. The panel of independent experts was going to consider whether to recommend emergency use authorization for the COVID-19 vaccine developed by Pfizer and BioNTech for children under 5. The FDA’s reversal means that it likely won’t be until at least mid-April before a COVID-19 vaccine is available to young children. The FDA says it will now wait for more data from Pfizer and BioNTech on how well a third dose of the vaccine works in children 6-months through 4-years-old. Data, so far, show that while a two-dose regimen of the vaccine is safe in this age group, it was not effective at creating enough of an immune response.
Listen to the latest episode of the Net Assets podcast.
